Sara Golbahari1, Seyyed Meysam Abtahi Froushani2. 1. Department of Microbiology, Faculty of Veterinary Medicine, Urmia University, Urmia, Iran. 2. Department of Microbiology, Faculty of Veterinary Medicine, Urmia University, Urmia, Iran. Electronic address: sm.abtahi@urmia.ac.ir.
Abstract
PURPOSE: Given to the anti-inflammatory effect of Nicotine and Thymol, this study was done to evaluate the effects of co-administration of Nicotine and Thymol on the clinical aspects, and immunity responses in Freund's complete adjuvant (FCA)-induced RA in Wistar rat. METHODS: The study population contained a total of 50 male Wistar rats with a weight range 150 ± 7 g, which RA was induced through FCA at them. These animals were randomly allocated into five groups (n = 10): RA rats treated with PBS (100 mg/kg orally), RA rats treated with Thymol (100 mg/kg orally), RA rats treated with Nicotine (2.5mg/kg-orally), and RA rats treated with combined Nicotine and Thymol (half doses with each one-orally). All treatments were initiated at day seven p.i. when all rats showed a clinical score of ≥1. Clinical symptoms of the disease were recorded every other day until the day 23 p.i. RESULTS: Obtained data revealed the combination therapy reduced the severity of the disease and improved weight-gaining more profound than each medication alone. Furthermore, combination therapy caused a reduction in some hematological and biochemical RA parameters, such as Rheumatoid factor, C-Reactive Protein, Nitric oxide, Myeloperoxidase, IL-1, and IL-17 more impressive than each treatment alone. Interestingly, the combination therapy with half doses of Nicotine and Thymol did not have any synergistic advantage in anti-proliferation effect, and therefore immunosuppression side effect compared with using each of agents alone. CONCLUSION: Collectively, it is possible that combination therapy can be applied as a beneficial strategy to control RA.
PURPOSE: Given to the anti-inflammatory effect of Nicotine and Thymol, this study was done to evaluate the effects of co-administration of Nicotine and Thymol on the clinical aspects, and immunity responses in Freund's complete adjuvant (FCA)-induced RA in Wistar rat. METHODS: The study population contained a total of 50 male Wistar rats with a weight range 150 ± 7 g, which RA was induced through FCA at them. These animals were randomly allocated into five groups (n = 10): RArats treated with PBS (100 mg/kg orally), RArats treated with Thymol (100 mg/kg orally), RArats treated with Nicotine (2.5mg/kg-orally), and RArats treated with combined Nicotine and Thymol (half doses with each one-orally). All treatments were initiated at day seven p.i. when all rats showed a clinical score of ≥1. Clinical symptoms of the disease were recorded every other day until the day 23 p.i. RESULTS: Obtained data revealed the combination therapy reduced the severity of the disease and improved weight-gaining more profound than each medication alone. Furthermore, combination therapy caused a reduction in some hematological and biochemical RA parameters, such as Rheumatoid factor, C-Reactive Protein, Nitric oxide, Myeloperoxidase, IL-1, and IL-17 more impressive than each treatment alone. Interestingly, the combination therapy with half doses of Nicotine and Thymol did not have any synergistic advantage in anti-proliferation effect, and therefore immunosuppression side effect compared with using each of agents alone. CONCLUSION: Collectively, it is possible that combination therapy can be applied as a beneficial strategy to control RA.